Novel method to slow ventricular rate
AssigneeInCarda Therapeutics, Inc.
InventorsLuiz BELARDINELLI, Rangachari NARASIMHAN, Carlos SCHULER
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, formulations, and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using selective β1 adrenergic receptor blockers. Also disclosed herein are methods, formulations, and kits for treating a heart condition via inhalation or intranasal spray administration of selective β1 adrenergic receptor blocker and class I antiarrhythmic agent.
Claims31
A method of treating a subject suffering from atrial arrhythmia, comprising:
- administering to said subject via inhalation a therapeutically effective amount of a β1-selective adrenergic receptor blocker,
- thereby inducing cardioversion of said atrial arrhythmia in said subject and slowing atrioventricular (AV) node conduction during said cardioversion.
A method of treating a subject suffering from atrial arrhythmia, comprising:
- administering to said subject via inhalation a therapeutically effective amount of a β1-selective adrenergic receptor blocker and a therapeutically effective amount of class I antiarrhythmic agent.
5-8. (canceled)
(canceled)
13-17. (canceled)
(canceled)
(canceled)
25-29. (canceled)
32-38. (canceled)
The method of claim 38, wherein said β1-selective adrenergic receptor blocker is administered up to about 90 minutes earlier than said dosage of said class I antiarrhythmic agent.
41-47. (canceled)
50-59. (canceled)
61-63. (canceled)
A kit comprising:
- a first unit dose comprising a β1-selective adrenergic receptor blocker;
- and
- a second unit dose comprising a class I antiarrhythmic agent.
65-94. (canceled)
Dependencies are inferred from the claim text.